type 2 diabetes - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,829 +0.67%

DJIA 48,258 +0.73%

Nasdaq 25,057 +0.65%

DAX 23,890 -0.31%

Gold $4,196 +0.16%

Oil $98.06 +1.42%

BTC $72,031 +0.93%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,214 +0.25%

S&P 500 6,829 +0.67%

DJIA 48,258 +0.73%

Nasdaq 25,057 +0.65%

DAX 23,890 -0.31%

Gold $4,196 +0.16%

Oil $98.06 +1.42%

BTC $72,031 +0.93%

VIX 20.48 -15.65%

EUR/USD 1.1785 -0.02%

ETH $2,214 +0.25%

type 2 diabetes

Eli Lilly Retatrutide injection pen symbolizing triple-agonist diabetes and obesity treatment boom

Pharma & Healthcare·Stocks·USA

Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock

By Maik Kemper • Mar 19, 2026

Eli Lilly Retatrutide injection pen symbolizing triple-agonist diabetes and obesity treatment boom

Pharma & Healthcare·Stocks·USA

Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock

By Maik Kemper • Mar 19, 2026

Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in…